HMGCR and coronary artery disorder: As the atheroprotective effect of 2-HOBA treatment is independent of any action on serum cholesterol levels, 2-HOBA offers real therapeutic potential for decreasing the residual CAD risk that persists in patients treated with HMG-CoA reductase inhibitors.